Candel Therapeutics Inc
CADL6.223USD
-0.067-1.07%
交易中 （美東）報價延遲15分鐘
306.44M總市值
虧損本益比TTM
關於 Candel Therapeutics Inc 公司
Candel Therapeutics, Inc. 是一家臨牀階段的生物製藥公司。該公司專注於開發現成的多模態生物免疫療法，以引發個性化、系統性的抗腫瘤免疫反應，幫助患者對抗癌症。該公司已建立兩個臨牀階段的多模態生物免疫療法平臺，分別基於新型轉基因腺病毒和單純皰疹病毒 (HSV) 基因構建體。CAN-2409 是腺病毒平臺的主要候選產品，目前正在進行非小細胞肺癌 (NSCLC)、邊緣可切除胰腺癌和侷限性非轉移性前列腺癌的臨牀試驗。CAN-3110 是 HSV 平臺的主要候選產品，目前正在進行一項由研究者發起的複發性高級別膠質瘤 (HGG) I 期臨牀試驗。其 enLIGHTEN 發現平臺利用人體生物學和高級分析來爲實體瘤創造新的病毒免疫療法。
公司簡介
公司代碼CADL
公司名稱Candel Therapeutics Inc
上市日期Jul 27, 2021
CEODr. Paul Peter Tak, M.D., Ph.D.
員工數量38
證券類型Ordinary Share
年結日Jul 27
公司地址117 Kendrick Street,
城市NEEDHAM
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編02494
電話16179165445
網址https://www.candeltx.com/
公司代碼CADL
上市日期Jul 27, 2021
CEODr. Paul Peter Tak, M.D., Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Christopher (Chris) Martell
Mr. Christopher (Chris) Martell
Independent Director
Independent Director
435.51K
--
Dr. Paul Peter Tak, M.D., Ph.D.
Dr. Paul Peter Tak, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
268.57K
+18.97%
Dr. Francesca Barone, M.D., Ph.D.
Dr. Francesca Barone, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
100.81K
+4.44%
Mr. Charles Schoch
Mr. Charles Schoch
Chief Financial Officer
Chief Financial Officer
43.39K
+14.07%
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
Independent Director
Independent Director
38.03K
--
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00K
--
Dr. Edward J. Benz, Jr., M.D.
Dr. Edward J. Benz, Jr., M.D.
Independent Director
Independent Director
--
--
Ms. Seshu Tyagarajan, Ph.D.
Ms. Seshu Tyagarajan, Ph.D.
Chief Technical and Development Officer
Chief Technical and Development Officer
--
--
Mr. Paul B. Manning
Mr. Paul B. Manning
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. W. Garrett Nichols, M.D.
Dr. W. Garrett Nichols, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Christopher (Chris) Martell
Mr. Christopher (Chris) Martell
Independent Director
Independent Director
435.51K
--
Dr. Paul Peter Tak, M.D., Ph.D.
Dr. Paul Peter Tak, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
268.57K
+18.97%
Dr. Francesca Barone, M.D., Ph.D.
Dr. Francesca Barone, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
100.81K
+4.44%
Mr. Charles Schoch
Mr. Charles Schoch
Chief Financial Officer
Chief Financial Officer
43.39K
+14.07%
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
Independent Director
Independent Director
38.03K
--
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00K
--
收入明細
FY2024
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q3
暫無數據
地區USD
名稱
營收
佔比
United States
0.00
0.00%
業務
地區
暫無數據
股東統計
更新時間: 5月24日 週六
更新時間: 5月24日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
13.50%
Manning (Paul B.)
5.38%
Acorn Capital Advisors, LLC
4.92%
Baker Bros. Advisors LP
4.64%
Aguilar-Cordova (Estuardo)
4.61%
Other
66.94%
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
13.50%
Manning (Paul B.)
5.38%
Acorn Capital Advisors, LLC
4.92%
Baker Bros. Advisors LP
4.64%
Aguilar-Cordova (Estuardo)
4.61%
Other
66.94%
股東類型
持股股東
佔比
Investment Advisor
29.01%
Individual Investor
16.48%
Investment Advisor/Hedge Fund
6.21%
Hedge Fund
5.99%
Corporation
2.48%
Research Firm
0.64%
Bank and Trust
0.09%
Pension Fund
0.02%
Insurance Company
0.02%
Other
39.06%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
162
31.98M
60.95%
-104.17K
2025Q1
160
30.10M
67.51%
-1.81M
2024Q4
131
27.38M
62.24%
+9.09M
2024Q3
115
17.10M
48.26%
-703.44K
2024Q2
98
16.89M
49.23%
+872.97K
2024Q1
67
14.85M
50.59%
-1.40M
2023Q4
65
14.94M
51.56%
-1.48M
2023Q3
68
15.61M
53.96%
-846.00K
2023Q2
65
15.70M
54.30%
-590.47K
2023Q1
64
16.17M
55.93%
-250.07K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Fidelity Management & Research Company LLC
7.09M
13.5%
+766.60K
+12.13%
Mar 31, 2025
Manning (Paul B.)
2.82M
5.38%
+500.00K
+21.52%
Apr 21, 2025
Acorn Capital Advisors, LLC
2.58M
4.92%
+428.26K
+19.90%
Jun 25, 2025
Baker Bros. Advisors LP
2.44M
4.64%
-544.79K
-18.27%
Mar 31, 2025
Aguilar-Cordova (Estuardo)
2.42M
4.61%
+190.92K
+8.57%
Apr 21, 2025
Aguilar (Laura K)
2.36M
4.49%
-690.05K
-22.65%
Apr 21, 2025
The Vanguard Group, Inc.
1.74M
3.31%
+396.95K
+29.64%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.61M
3.06%
+515.63K
+47.27%
Mar 31, 2025
BKB Growth Investments LLC
1.30M
2.48%
+750.00K
+135.44%
Apr 21, 2025
Portolan Capital Management, L.L.C.
881.18K
1.68%
+127.44K
+16.91%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
ALPS Medical Breakthroughs ETF
0.17%
Vanguard US Momentum Factor ETF
0.08%
iShares Micro-Cap ETF
0.05%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Value ETF
0%
查看更多
ALPS Medical Breakthroughs ETF
佔比0.17%
Vanguard US Momentum Factor ETF
佔比0.08%
iShares Micro-Cap ETF
佔比0.05%
iShares Russell 2000 ETF
佔比0.01%
ProShares UltraPro Russell2000
佔比0.01%
iShares Russell 2000 Growth ETF
佔比0.01%
Proshares Ultra Russell 2000
佔比0.01%
Global X Russell 2000 ETF
佔比0.01%
ProShares Hedge Replication ETF
佔比0.01%
iShares Russell 2000 Value ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
